5 results about "Buffy coat" patented technology

A processing device includes a pump system, a valve system, a centrifuge, and a controller. A fluid flow circuit is mounted to the device to execute a procedure in which whole blood is processed into a red blood cell product, a plasma product, and a platelet concentrate product. The blood is first separated into red blood cells, buffy coat, and plasma using the centrifuge, with the red blood cells and plasma being removed from the centrifuge, while the buffy coat remains in the centrifuge. The fluid remaining in the centrifuge is circulated through the centrifuge to form a homogenous mixture. Once the mixture is formed, it is separated in the centrifuge into platelet concentrate and red blood cells. A platelet product is then collected by using whole blood or previously collected red blood cells to push the platelet concentrate from the centrifuge to a collection container.

1. Name of the design product: bracelet (blood cell separation sheet). 2. Use of the design product: the design product is a bracelet worn on the wrist, which activates health conditions naturally through physical therapy in a non-drug and non-chemical way. 3. Design points of the design product: in the combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view 1.

The utility model relates to a device for preparing platelet-rich plasma with less blood volume. The device comprises a preparation tube unit, an upper tube cover unit, an isolation unit and a lower tube cover unit, the platelet-rich plasma preparation device has the advantages that by changing the structure of the preparation tube unit, the platelet-rich plasma preparation device can be suitable for treatment of small animals or pets; the volume of blood contained in the preparation tube unit is reduced, so that the centrifugation time is shortened, and the risks of infection and blood coagulation are reduced; besides, after the blood is centrifugally separated, a lower tube cover unit is arranged and is in threaded connection with a preparation tube unit, so that the lower tube cover unit can be rotated to adjust the volume of a fourth cavity of the preparation tube unit, the buffy yellow layer by layer is positioned in a third cavity, and the plasma is completely positioned in a second cavity of the preparation tube unit; therefore, subsequent extraction by medical staff is facilitated.

The invention discloses the in vitro use of a non-LTR RTE biomarker, such as LINE-1, to diagnose neurodegenerative diseases, particularly tauopathies. The diagnosis is based on identifying an increase in the number of LINE-1 copies in the biological fluids of an individual, and the difference in the number of copies of a non-LTR RTE, LINE-1, per ng of DNA in a biological sample, preferably a buffy coat, between healthy subjects (Control) and ill patients. The tauopathies are: Alzheimer's Disease (EA), Mild Cognitive Impairment (DCL), Progressive Supranuclear Palsy (PSP) / Corticobasal Syndrome (SCB) and Frontotemporal Dementia (DFT). The invention also relates to a kit comprising means for detecting the biomarker in a biological sample obtained from the individual and means for comparing the levels of the biomarker of interest in the sample with a control reference obtained from healthy individuals, and relates to an in vitro method for detecting a non-LTR RTE, such as LINE-1, in a biological sample.

The methods, systems, and compositions provided herein allow improved methods for detecting non-cancer somatic mutations in a subject by measuring buffy coat somatic mutations in order to improve identification of samples with age related somatic mutations.